Back grey_arrow_rt.gif
Trimeris settles patent dispute over Fuzeon
Trimeris Inc. will pay Novartis just over $2.4 million as part of a patent dispute settlement with Novartis over the HIV drug Fuzeon, the company said Monday.
Roche is Trimeris' marketing partner on the drug.
Under the terms of the settlement, the Roche and Trimeris collaboration will continue to sell Fuzeon under a license to Novartis. The companies have agreed to pay royalties to Novartis. Aside from the $2.4 million, Trimeris will also pay an additional $133,000 to Novartis no later than Oct. 31.
Meanwhile, Roche relieved Trimeris of any obligation to repay deferred marketing expenses.
  icon paper stack View Older Articles   Back to Top